CFAP418-AS1 Gene Amplification is Associated with Decreased Pancreatic Cancer Patient’s Survival Rate
Abstract – Identifying specific biomarkers associated with pancreatic ductal adenocarcinoma (PDAC) patients’ survival at an early stage is essential. After analyzing 1,206 pancreatic cancer patients’ genomic data provided by cBioPortal database, an open web-based platform for cancer genomics, we found that 14 genes are significantly amplified in the deceased patient group compared to the living patient group. Among 14 genes, we found that CFAP418-AS1 amplified patients (n= 9) are significantly associated with decreased median overall survival month (9.14 months) when compared with the median overall survival month (24.9 months) of CFAP418-AS1 non-amplified patients (n= 457). To determine how CFAP418-AS1 amplification decreased patients’ survival rates, we performed an in vitro assay to overexpress CFAP418-AS1 in ASPC1 pancreatic cancer cell line. In addition, Prestoblue assay indicated that overexpression of CFAP418-AS1 increased cell proliferation. Therefore, CFAP418-AS1 may function as an oncogene and decrease survival rates of pancreatic cancer patients by increasing cancer cell proliferation. Further investigation of the mechanisms affecting CFAP418-AS1 dysregulation will provide insights into the molecular differences underpinning pancreatic cancer’s survival rate.